Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cymbi Drops is an oral pediatric carminative and antiflatulent formulation developed by Juggat Pharma, a division of Jagdale Industries. It is a fixed-dose combination containing simethicone, dill oil, and fennel oil. Simethicone acts as a physical surfactant that reduces the surface tension of gas bubbles in the gastrointestinal tract, causing them to coalesce into larger bubbles that are more easily expelled. Dill oil and fennel oil are natural carminatives that help soothe the intestinal mucosa, reduce smooth muscle spasms, and improve intestinal motility. Cymbi Drops is primarily indicated for the relief of infant colic, griping pain, flatulence, bloating, and hiccups in infants and young children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cymbi Drops.